Determination of the 50% human infectious dose for Norwalk virus
- PMID: 24253285
- PMCID: PMC3952671
- DOI: 10.1093/infdis/jit620
Determination of the 50% human infectious dose for Norwalk virus
Abstract
Background: Noroviruses are the most common cause of gastroenteritis in the United States. An understanding of the infectious dose of these viruses is important for risk assessment studies.
Methods: Healthy adults were enrolled in a randomized, double-blind, placebo-controlled evaluation of different dosages of Norwalk virus. Eligible subjects were monitored for clinical gastroenteritis, and infection status was determined. The presence of virus in vomitus was also assessed.
Results: Fifty-seven persons were enrolled; 8 received placebo and an additional 8 persons were considered to be nonsusceptible on the basis of being secretor negative. Twenty-one persons were infected (all blood group O or A), and 67% of those infected developed viral gastroenteritis. The 50% human infectious dose was calculated to be 3.3 reverse transcription polymerase chain reaction units (approximately 1320 genomic equivalents [gEq]) for secretor-positive blood group O or A persons and 7.0 (approximately 2800 gEq) for all secretor-positive persons. The time of illness onset was inversely correlated with inoculum dose. The maximal concentration of virus shedding was higher for persons with gastroenteritis. Norwalk virus was identified in 15 of 27 (56%) vomitus samples at a median concentration of 41 000 gEq/mL.
Conclusions: The 50% human infectious dose measured is higher than previous estimates and similar to that of other RNA viruses. Clinical Trials Registration NCT00138476.
Keywords: infectious dose; norovirus; secretor; serology; virus shedding.
Figures
Comment in
-
Reply to Kirby et al.J Infect Dis. 2015 Jan 1;211(1):167. doi: 10.1093/infdis/jiu382. Epub 2014 Jul 10. J Infect Dis. 2015. PMID: 25015947 Free PMC article. No abstract available.
-
Two human challenge studies confirm high infectivity of Norwalk virus.J Infect Dis. 2015 Jan 1;211(1):166-7. doi: 10.1093/infdis/jiu385. Epub 2014 Aug 13. J Infect Dis. 2015. PMID: 25121553 No abstract available.
References
-
- Gastanaduy PA, Hall AJ, Curns AT, Parashar UD, Lopman BA. Burden of norovirus gastroenteritis in the ambulatory setting—United States, 2001–2009. J Infect Dis. 2013;207:1058–65. - PubMed
-
- Dolin R, Blacklow NR, DuPont H, et al. Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. Proc Soc Exp Biol Med. 1972;140:578–83. - PubMed
-
- Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis. 2012;206:1386–93. - PubMed
-
- Graham DY, Jiang X, Tanaka T, Opekun AR, Madore HP, Estes MK. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis. 1994;170:34–43. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
